Ilginatinib is under clinical development by NS Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ilginatinib’s likelihood of approval (LoA) and phase transition for Myelofibrosis took place on 12 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ilginatinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ilginatinib overview

ilginatinib is under development for the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis , severe pneumonia and acute respiratory distress syndrome caused due covid-19. The drug candidate is administered orally as a tablet. NS-018 is a small molecule which acts by targeting JAK2/Src.

NS Pharma overview

NS Pharma is a pharmaceutical company that develops drugs for muscular disorders. Its pipeline portfolio includes Phase II stage investigational candidates, NS-018 to treat hematologic malignancies such as myelofibrosis, NS-065 and NCNP-01 for the treatment of orphan diseases such as duchenne muscular dystrophy.

Quick View Ilginatinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Ilginatinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: NS Pharma
  • Originator: Nippon Shinyaku
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.